Aptose Biosciences Inc. (APS) Analysts See $-0.15 EPS as of May, 10

May 3, 2018 - By Matthew Medley

On May, 10. Investors wait Aptose Biosciences Inc. (TSE:APS) to report its quarterly earnings, according to Zacks. The earnings per share diference is $0.10 or 40.00 % up from last years number. Previous year: $-0.25; Analysts forcast: $-0.15. Last quarter $-0.15 earnings per share was reported. Analysts sees 0.00 % EPS growth this quarter. APS reached $4.16 during the last trading session after $0.06 change.Currently Aptose Biosciences Inc. is after 0.00% change in last May 3, 2017. APS has 13,800 shares volume. The stock underperformed the S&P500 by 11.55%.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada.The firm is worth $127.72 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.Currently it has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.